Order Article Reprints

Adderson E, Allison KJ, Branum K, Sealy RE, Jones BG, Surman SL, Penkert RR, Hayden RT, Russell CJ, Portner A, et al. Intranasal Sendai Virus Vaccination of Seropositive Children 1 to 2 Years of Age in a Phase I Clinical Trial Boosts Immune Responses Toward Human Parainfluenza Virus Type 1. Vaccines. 2025; 13(4):430. https://doi.org/10.3390/vaccines13040430

Adderson, Elisabeth, Kim J. Allison, Kristen Branum, Robert E. Sealy, Bart G. Jones, Sherri L. Surman, Rhiannon R. Penkert, Randall T. Hayden, Charles J. Russell, Allen Portner, and et al. 2025. "Intranasal Sendai Virus Vaccination of Seropositive Children 1 to 2 Years of Age in a Phase I Clinical Trial Boosts Immune Responses Toward Human Parainfluenza Virus Type 1" Vaccines 13, no. 4: 430. https://doi.org/10.3390/vaccines13040430

Adderson, E., Allison, K. J., Branum, K., Sealy, R. E., Jones, B. G., Surman, S. L., Penkert, R. R., Hayden, R. T., Russell, C. J., Portner, A., Slobod, K. S., & Hurwitz, J. L. (2025). Intranasal Sendai Virus Vaccination of Seropositive Children 1 to 2 Years of Age in a Phase I Clinical Trial Boosts Immune Responses Toward Human Parainfluenza Virus Type 1. Vaccines, 13(4), 430. https://doi.org/10.3390/vaccines13040430